Tranexamic acid	Placebo	Baseline characteristics	-1	-1	<td align="left" colspan="1" rowspan="1">Final</td><td align="left" colspan="1" rowspan="1">36.3(0.8)</td><td align="left" colspan="1" rowspan="1">34.7(1.1)</td><td align="left" colspan="1" rowspan="1">36.6(1.3)</td><td align="left" colspan="1" rowspan="1">34.8(1.4)</td>
Tranexamic acid	Placebo	Mean volume of drainage fluid	809	1107	The mean volume of drainage fluid was 270 ml and 620 ml for unilateral(U/L) and bilateral(B/L) TKR patients in placebo group. Whereas it was 160ml and 286 ml respectively in unilateral(U/L) and bilateral(B/L) TKR patients who received tranexamic acid. This was considered statistically significant.
Tranexamic acid	Placebo	Units of PRBC needed	1108	1216	Control group patients received 26 units of PRBC as compared to 4 units in tranexamic acid groups (p<0.001).
Tranexamic acid	Placebo	Baseline characteristics	8245	8407	There were no significant differences between the patients with respect to age, sex, weight, duration of surgery and fall in core temperature. (Table 1)(p > 0.05)
Tranexamic acid	Placebo	Deep vein thrombosis	9362	9531	None of the patients in any of the groups had clinical evidence of deep vein thrombosis observed daily for seven days or biochemical evidence of coagulation abnormality.
Tranexamic acid	Placebo	Deep vein thrombosis	1259	1332	None of the patients in any of the groups developed deep vein thrombosis.
